Platelet and endothelial activation are requisites for the development of antiphospholipid syndrome

Annals of the Rheumatic Diseases

Volumn 63, Issue 5, 2004, Pages 600-601

  Del Rio Garcia E ^a   Rodriguez C ^a   Rodriguez Martorell J ^a   Serrano, A ^a   Giron Gonzalez J A ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; CELL ADHESION MOLECULE; COUMARIN DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLYCOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOPLASTIN TIME; VEIN THROMBOSIS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; MALE; PLATELET ACTIVATION; PROSPECTIVE STUDIES;

EID: 11144357426     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.010694     Document Type: Article

References (10)

1. Levine JS, Branch W, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752-63.
2. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SA, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk of ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997.
3. Ginsberg JS, Wells PS, Brill-Edwards P, Donovan K, Moffatt K, Johnston M, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995;86:3685-91.
4. Elias M, Eldor A. Thromboembolism in patients with the "lupus"-type circulating anticoagulant. Arch Intern Med 1984;144:510-15.
5. Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000;43:55-64.
6. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid síndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001;115:451-9.
7. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309-11.
8. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995;74:1185-90.
9. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68:215-22.
10. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992;148:3885-90.